Solid Biosciences Inc. SLDB 深 滬
已收盤 02-06 16:00:00 美东时间
6.52
+0.290
+4.65%
華盛通- 最 高6.63
- 今 開6.40
- 成交量 188.89万股
- 最 低 6.35
- 昨 收 6.23
- 總市值 5.08亿
- 52周最高 7.37
- 市盈率 靜 --
- 換手率 2.42%
- 52周最低 2.41
- 委 比 -63.73%
- 總股本 7791.02万
- 歷史最高 822.60
- 量 比 1.71
- 振 幅 4.49%
- 歷史最低 1.81
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
Solid Biosciences' SGT-212 Secures FDA Orphan Drug, Fast Track And Rare Pediatric Disease Designations; First Patient Dosed In Phase 1b FALCON Trial, Initial Data Expected H2 2026
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations -- Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026,
01-13 05:16
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Solid Biosciences' SGT-212 has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for treating Friedreich’s ataxia (FA). The first participant in the Phase 1b FALCON trial has been dosed, with initial data expected in H2 2026, contingent on enrollment. SGT-212 uses dual-route administration to target FA's neurological, cardiac, and systemic effects. The FALCON trial evaluates its safety and tolerability in FA patients w...
01-12 21:15
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. announced that CEO Bo Cumbo will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be available live and via replay on the company's website. Solid focuses on gene therapies for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia, aiming to improve lives of patients with devastating rare diseases.
01-06 13:00
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. has granted 7,000 restricted stock units (RSUs) to a newly hired employee. The RSUs vest equally over four years, contingent on continued employment. This grant was made under the company's 2024 Inducement Stock Incentive Plan to attract the employee. Solid Biosciences, a precision genetic medicine company, focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases, aiming to improve the lives...
01-05 21:15
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-24 17:33
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Solid Biosciences Inc. announced that Duchenne muscular dystrophy (Duchenne) has been added to the U.S. Department of Health and Human Services' Recommended Uniform Screening Panel (RUSP),推荐作为新生儿筛查项目。Solid Biosciences是推动杜兴氏肌肉营养不良症新生儿筛查的重要支持者，预计这一举措将加速早期诊断，改善患者预后。公司正在开发的SGT-003基因疗法具有独特设计，可改善肌肉血流并减少肌肉分解，有望成为同类最佳治疗方案。
2025-12-16 21:51
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Inc. announced it will present data on its next-generation AAV-SLB101 capsid and cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists Forum. Dr. Gabriel Brooks, the company’s Chief Medical Officer, will deliver two presentations, lead a panel discussion, and exhibit a poster. Dr. Nicolas Christoforou, Head of Discovery and Translational Development, will also present on preclinical research for CPVT gene...
2025-12-08 13:00
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
